Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • News
    • Pharmaceuticals
    • Unichem, Macleods...

    Unichem, Macleods Pharma recall drugs from US market

    Medical Dialogues BureauWritten by Medical Dialogues Bureau Published On 2020-02-17T15:09:14+05:30  |  Updated On 17 Feb 2020 3:09 PM IST
    Unichem, Macleods Pharma recall drugs from US market

    The reason for the voluntary ongoing nationwide is "failed impurities/degredation specifications.

    New Delhi: Drug firms Unichem Pharmaceuticals and Macleods Pharma are recalling various lots of tablets used for the treatment of high blood pressure and diabetes from the US market, according to the latest enforcement report of the American health regulator. Unichem Pharmaceuticals USA Inc is recalling 1.91 crore units of Clonidine Hydrochloride tablets used for treating high blood pressure from the US market, the report said.

    The company is recalling units of Clonidine Hydrochloride Tablets, USP 0.1 mg manufactured by Unichem Laboratories Ltd at Goa facility, it added.

    The reason for the voluntary ongoing nationwide is "failed impurities/degredation specifications. This recall is initiated as a precautionary measure due to potential migration of Benzophenone at very low level into the product from container label, the United States Food and Drug Administration (USFDA) said.

    On the other hand, Macleods Pharma USA Inc is recalling 4,694 bottles of Pioglitazone and Metformin Hydrochloride tablets used to treat high blood sugar levels caused by type 2 diabetes from the US market.

    The company is recalling Pioglitazone and Metformin Hydrochloride tablets USP 15 mg/500 mg, manufactured by Macleods Pharmaceuticals Ltd at its Baddi facility in Himachal Pradesh, the report said.

    The reason for the voluntary nationwide ongoing recall is on account of it being "sub potent drug: out of specification assay result, below specification, for two lots of Pioglitazone And Metformin Hydrochloride tablets," the USFDA said.

    Both the recalls by the companies are class III recalls, it added.

    Read also: Unichem Labs gets USFDA nod for generic version of Tenormin tablets

    As per the USFDA, a class III recall is initiated in a "situation in which use of, or exposure to, a violative product is not likely to cause adverse health consequences".

    Read also: Unichem Lab shares jump over 7 pc after USFDA nod for Atenolol tablets

    Macleods PharmaUnichem Pharmaceuticals
    Source : PTI

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Medical Dialogues Bureau
    Medical Dialogues Bureau

      Medical Dialogues Bureau consists of a team of passionate medical/scientific writers, led by doctors and healthcare researchers.  Our team efforts to bring you updated and timely news about the important happenings of the medical and healthcare sector. Our editorial team can be reached at editorial@medicaldialogues.in. Check out more about our bureau/team here

      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok